Seeking Alpha

Levels of beta amyloid, a protein linked with Alzheimer's, increased in the blood of patients...

Levels of beta amyloid, a protein linked with Alzheimer's, increased in the blood of patients treated with Eli Lilly's (LLY) solanezumab in two Phase III trials, suggesting that the protein was removed from the brain as intended. As already disclosed, Solanezumab seems to be able to slow Alzheimer's progression in patients with mild symptoms, so the latest finding provides validity to the belief that amyloid is a cause.
Comments (2)
  • findingZzero
    , contributor
    Comments (5) | Send Message
     
    I remember when I started as a chemist in drug discovery, my mentor told me a cautionary tale about data interpretation. You might call it a pharmaceutical urban legend (from the '60's). A company was excited about an expt'l drug that dramatically lowered blood cholesterol, only to find that it was accumulating as plaque in the arteries. Be careful how you interpret the data.
    30 Oct 2012, 02:12 PM Reply Like
  • Nysejob
    , contributor
    Comments (4) | Send Message
     
    Beware of interpretations of data from two failed studies when Pharmaceutical Company President has failed data re- interpreted and comes up with a conclusion that Failure 1 data (Expedition I )plus Failure 2 data (Expedition II) becomes potential 34% SUCCESS data...be careful....be VERY careful. Investigators can be encouraged to seek something that is really not there.. This is a horrible condition that deserves credible study, and not a Wheres Waldo? approach
    30 Oct 2012, 05:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs